Cooperation with The Defeat-NCD Partnership
Together with The Defeat-NCD Partnership, Boehringer Ingelheim aims to address key access to healthcare issues related to non-communicable diseases.
Search
Zongertinib positive results non-small cell lung cancer
Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients
Our Vision
At Boehringer Ingelheim, we have expanded our global research and development activities to tackle eye diseases, specifically those affecting the back of the eye.
collaboration-kings-college-london
Boehringer Ingelheim and the IoPPN at King’s College London partner to progress new therapeutic concepts in major depressive disorder and schizophrenia
Circular economy: Taking action to reduce plastic waste
The packaging department team at Yamagata, Japan, managed to reduce their waste plastic material for a greener and more sustainable tomorrow
Boehringer Ingelheim Innovation Prize
Find out more about how we’re providing valuable resources to life-science innovators to enable new and emerging science
Improving Access to Healthcare
According to the UN Sustainable Development Goals, almost half of the global population is not covered by essential health services.
Boehringer Ingelheim Second Transforming Science Day
World-renowned top scientists and companies in R&D take the stage at Boehringer Ingelheim’s second Transforming Science Day
Disentangling fibrosis
Fibrosis is an important area of research for Boehringer Ingelheim that is focusing on fibrotic conditions of the liver, lung, kidney, skin and gut.
Positive results Diabetic Macular Ischemia treatment
HORNBILL Phase I/II study shows positive results for potentially first ever Diabetic Macular Ischemia treatment
The Unwearable Collection™ Evolution
Get ready for the next stage of The Unwearable Collection™
New production center for Veterinary Public Health
Boehringer Ingelheim invests more than €200 million to establish a strategic production center for Veterinary Public Health in Lyon, France.
FOYA_Shanghai
Boehringer Ingelheim’s commercial manufacturing facility in Shanghai has been awarded as “Facility of the Year”
Unlocking Your Team’s Potential
Angela Shaw at the Women in Tech Global Conference
The GPP Forum
The generalized pustular psoriasis (GPP) Forum - a multistakeholder event collaborating for a new vision for people living with GPP
Generalized pustular psoriasis: Value of community support
Dr Clerisme-Beaty and Dr Strober MD, PhD discuss the importance of knowledge sharing, community support and challenges faced by those living with GPP.
Day and night: veterinary clinic for pet care
Our primary focus is supporting our vets to care for our animal friends, providing on-time medicines when needed. Learn how we do this in our daily lives.
Ann-Kathrin Koller
Diverse, caring, collaborative - Ann-Kathrin Koller on Boehringer Ingelheim
Daniel Kiesenhofer
Diverse, caring, collaborative - Daniel Kiesenhofer on Boehringer Ingelheim
Dirk Esser
Diverse, caring, collaborative - Dirk Esser on Boehringer Ingelheim
Agreement-to-acquire-NBE-Therapeutics
Boehringer Ingelheim to acquire NBE-Therapeutics to significantly enhance cancer pipeline portfolio with antibody-drug conjugates.
Partnering with Constantia Flexibles for augmented reality
Boehringer Ingelheim partnered with Constantia Flexibles to provide an innovative packaging solution which enhances the Nutraxin packaging with augmented reality features.
Uncommon_Mutations_Database
New database of published clinical outcomes from patients with uncommon EGFR mutations in advanced NSCLC treated with afatinib is available for global clinician use
Brigimadlin
MDM2-p53 antagonist
Award winning employers
Boehringer Ingelheim focuses on the wellbeing of its employees – and is therefore also a "Global Top Employer 2023".